La Reina schreef op 7 september 2020 12:18:
Salix Pharmaceuticals Ltd (SLXP) Salix, de beoogde partner met Nasdaq-notering voor Pharming?
Hoe kom ik hierop:
1.Men werkt (e) al samen : distributie in de VS/(ook destijds) voor Prophylaxe;
2.Salix is onderdeel van Bausch Health Companies Inc. (notering Canada) waarvan de geschiedenis terug gaat naar : Valeant! Iedere belegger in Pharming kent de geschiedenis van Valeant en de milestonebetalingen van Pharming, dus Pharming is bekend met dit bedrijf en heeft daar de relaties;
3.Ik ontdek steeds meer publicaties waarin Salix en Pharming in 1 adem genoemd
4.Bausch heeft ook een clinical trial Covid, dus dat komt goed uit (!).
5.Recentelijk flinke aflossing schulden Bausch met cash/behoorlijk wat CASH aanwezig, terwijl Salix het minder goed doet;
6. Salix heeft een sterk verkoopapparaat in de VS maar ook daarbuiten;
7. Salix altijd op zoek naar partners:
www.salix.com/research-development/pa...'
As one of the world’s largest specialty pharmaceutical companies, we are constantly searching for additional licensing and partnership opportunities within the field of gastroenterology'. Nog wat info voor de geínteresseerden: ad 2: geschiedenis Salix/relatie met Valeant: www.salix.com/about-us/historyad 3. wat voorbeelden:In addition, the recombinant human C1 esterase inhibitor conestat alfa (Ruconest; Pharming Group & Salix Pharmaceuticals, Bridgewater, NJ) is a specific inhibitor of the classical complement activation pathway which is currently approved for treatment of hereditary angioedema. This C1 inhibitor (C1-INH) is under consideration as an open-label, multicenter pilot trial in adult patients with SARS-CoV-2 pneumonia (“PROTECT-COVID-19” trial).www.ncbi.nlm.nih.gov/pmc/articles/PMC...www.frontiersin.org/articles/10.3389/...dm5migu4zj3pb.cloudfront.net/manuscri...ad 4: Bausch heeft ook een clinical trial Covid, dus dat komt goed uit (!):
www.fool.ca/2020/07/09/the-1-stock-id...Bausch has a drug that could help treat COVID-19
Papa said that he sees a return to business starting in the third quarter. The company is expanding its footprint in Canada.
Bausch is also part of the hunt to find ways to treat COVID-19, but not through a vaccine.
One of Bausch’s existing drugs, Virazole, which hospitals use to treat respiratory infections in infants and children, could help adults suffering from COVID-19.
In May, Bausch received approval from Health Canada to start a trial. Papa hopes to see results in six months.Verdere info: finance.yahoo.com/news/bausch-bhc-dow...The Salix segment revenues declined 21% year over year to $404 million due to the impact of the COVID-19 pandemic and loss of exclusivity of products in the segment, primarily Apriso. Sales of Xifaxan declined 12%.
The company’s finances are improving
Bausch currently has $912 million in cash and $1 billion available under its revolving credit facility, and its debt is not due until 2022. Thus, the company is well placed to withstand any storm from the point of view of liquidity.
www.marketbeat.com/stocks/TSE/BHC/
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.
www.marketwatch.com/story/bausch-to-r...Bausch to reduce debt by $100 million using cash from operations
Published: Aug. 31, 2020 at 7:08 a.m. ET
Bausch Health Cos. Inc. BHC, +2.00% said Monday it will reduce debt by $100 million using cash generated from operations. The drug company, the former Valeant, will redeem $100 million of its outstanding 5.875% notes that mature in 2023. Bausch has $23.4 billion of debt, according to FactSet. Shares were up 1% premarket, but have fallen 43% in the year to date, while the S&P 500 SPX, -0.81% has gained 8.6%.
Company profile:
www.dnb.com/business-directory/compan...Eerdere samenwerking:
www.marketscreener.com/quote/stock/PH... En nog wat info over de voormalige CFO (niet al te best)....www.cfo.com/regulation/2018/10/ex-sal...de.reuters.com/article/us-salix-sec-i...www.sec.gov/news/press-release/2018-221